Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
Two patients with relapsed acute promyelocytic leukaemia previously treated with all-trans retinoic acid (ATRA), were treated with a new synthetic retinoid, Am-80. In both patients pancytopenia gradually resolved without an increase in leukaemic cells, and differentiation of leukaemic cells was observed morphologically in bone marrow. Without the use of anti-leukaemic agents, both cases achieved complete remission (CR) on days 52 and 38 of treatment, respectively. On the day of CR, PML gene rearrangement and the t(15;17) translocation disappeared, though PML-RAR alpha chimaeric messenger RNA was still detected by reverse transcriptase polymerase chain reaction. Both patients then received conventional chemotherapy for consolidation of CR. These clinical experiences suggest that Am-80 may be an active agent for APL patients who have relapsed from ATRA-induced remission.
Takeuchi
M
M
Department of Internal Medicine, National Sanatorium Minami Okayama Hospital, Tsukubo Gun, Japan.
Yano
T
T
Omoto
E
E
Takahashi
K
K
Kibata
M
M
Shudo
K
K
Ueda
R
R
Ohno
R
R
Harada
M
M
D000328:Adult; D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use*
D001565:Benzoates; D013764:Tetrahydronaphthalenes; C061133:tamibarotene; D014212:Tretinoin